BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-65@pharmaconomics
DTSTAMP:20260707T021604Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:AMGN Phase 3 — Ocrelizumab (US)
DESCRIPTION:Phase 3 trial results for Ocrelizumab (US) in Relapsing-remitting Multiple Sclerosis (RRMS) are due Jan 15\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://clinicaltrials.gov/study/NCT06700343\n\nTrack it: https://pharmaconomics.com/e/65
URL:https://pharmaconomics.com/e/65
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:AMGN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR